Physician profile
Daniel Wilkinson
NPI 1215317128
$4,130.54
in general payments reported to CMS, 2019-2025
13 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $83.00 · 2022: $2,504 · 2024: $406 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,548.17 | 2022-2025 | Carpentier-Edwards Physio II Annuloplasty Ring, Sapien 3 Ultra Resilia |
| Atricure, INC. | $596.06 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Zimmer Biomet Holdings, INC. | $255.92 | 2024-2025 | Sternalock 360 System, Sternalock Blu System |
| Intuitive Surgical, INC. | $218.56 | 2022-2024 | |
| Pfizer INC. | $110.10 | 2024-2025 | |
| Medtronic, INC. | $95.89 | 2024-2025 | Autolog, Avalus, Freestyle |
| Portola Pharmaceuticals, LLC | $84.72 | 2019 | |
| Penumbra, INC. | $83.00 | 2020 | |
| Abiomed | $40.48 | 2024 | Impella |
| Corcym INC | $37.74 | 2025 | Perceval |
| Baxter Healthcare | $22.00 | 2022 | |
| Abbott Laboratories | $20.44 | 2024 | Navitor |
| Pacira Pharmaceuticals Incorporated | $17.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.